This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Comment on: "Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited‐Stage Diffuse Large B‐Cell Lymphoma of the Bone (the IELSG‐14 Study)". (23rd October 2014)
Record Type:
Journal Article
Title:
Comment on: "Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited‐Stage Diffuse Large B‐Cell Lymphoma of the Bone (the IELSG‐14 Study)". (23rd October 2014)
Main Title:
Comment on: "Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited‐Stage Diffuse Large B‐Cell Lymphoma of the Bone (the IELSG‐14 Study)"
Abstract : The conclusion of Ventre et al. is that patients with primary diffuse large B‐cell lymphoma (DLBCL) of bone should be treated with anthracycline‐based chemotherapy (the standard for all cases of DLBCL) with or without radiotherapy. The study suffers from several weaknesses that make the conclusion doubtful.